{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-038299","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.329837+00:00","generated_at":"2026-06-17T11:34:00.443093+00:00","sec_items":["2.03","1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Regeneron amends $720M lease financing to align covenants with Dec 2022 credit agreement","bullets":["Third A&R Participation Agreement aligns financial and operating covenants with credit agreement entered December 2022.","$720 million lease financing for corporate headquarters; maturity remains March 2027 with 5-year extension option.","Yield on advances unchanged, based on 1-month SOFR term rate plus spread and margin tied to debt rating/leverage.","No new borrowing; amendment and restatement of existing facility; lease term extended previously to 2027.","Regeneron guarantees obligations; subsidiary guarantors only join if they have borrowings under the credit agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-038299","json":"https://secwatch.observer/filing/0001104659-23-038299.json","markdown":"https://secwatch.observer/filing/0001104659-23-038299.md","text":"https://secwatch.observer/filing/0001104659-23-038299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465923038299/0001104659-23-038299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465923038299/tm2310647d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T11:34:00.443093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}